SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
1.020
-0.030 (-2.86%)
At close: Apr 24, 2026, 4:00 PM EDT
1.030
+0.010 (0.98%)
After-hours: Apr 24, 2026, 7:12 PM EDT
SCYNEXIS Earnings Call Transcripts
Fiscal Year 2026
-
Acquisition of SCY-770 marks a strategic shift to rare renal diseases, targeting ADPKD with a promising, selective AMPK activator. The deal provides global rights, strong IP, and financial runway to 2029, positioning the company for leadership in a large, underserved market.
Fiscal Year 2024
-
Key updates included progress on antifungal partnerships, especially with GSK, and advancement of next-generation compound SCY-247 toward first-in-human studies by year-end. The company maintains a strong financial position and is recognized as a leader in antifungal innovation.